乌干达婴儿中低出生体重和早产而非疟疾化学预防与肺炎球菌疫苗免疫原性降低相关
在乌干达高疟疾传播区嵌套于MIC-DroP试验的202名婴儿中,195名完成三剂PCV-10系列。婴儿疟疾化学预防或疟疾暴露与PCV-10免疫原性或血清转化无关,而低出生体重(<2500g)和早产(<37周)与抗体 fold-change 降低及血清转化 odds 降低相关。
要点
- 疟疾暴露或PMC未显著影响PCV-10抗体反应。
- 低出生体重与PCV-10免疫原性降低82%及血清转化OR=0.19相关。
- 早产与PCV-10免疫原性降低79%及血清转化OR=0.181相关。
核心结论
- 在疟疾流行区,早期疟疾暴露和化学预防未可测量地改变PCV-10抗体反应,但低出生体重和早产与疫苗免疫原性降低相关。
研究设计与样本
- 研究嵌套于MIC-DroP试验(NCT04978272),选取202名婴儿,195名完成三剂PCV-10系列,采用广义估计方程模型分析。
主要发现
- 婴儿PMC或入组至14周疟疾暴露与PCV-10免疫原性或血清转化无关。
- 低出生体重(<2500g)与抗体fold-change降低82%(95%CI:43-94%,p=0.003)及血清转化odds降低(OR=0.19,95%CI:0.06-0.57,p=0.003)相关。
- 早产(<37周)与抗体fold-change降低79%(95%CI:24-94%,p=0.018)及血清转化odds降低(OR=0.181,95%CI:0.05-0.65,p=0.009)相关。
关键数值与推荐
- 免疫原性量化为8至24周龄IgG浓度的log10 fold-change,血清转化为24周时≥0.35 μg/mL。
临床怎么用
- 对于低出生体重或早产婴儿,应关注PCV-10免疫应答可能降低,考虑加强监测或免疫策略调整。
局限性
- 研究样本量有限(202名婴儿),且为观察性分析,不能排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. METHODS: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. RESULTS: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43-94%] antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19 [95% CI: 0.06-0.57], p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24-94%] antibody fold-change, p=0.018; OR=0.181 [95% CI: 0.05-0.65], p=0.009). CONCLUSION: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
引用
- Musinguzi K, Sbarra AN, Bach F, et al. Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants. J Infect Dis. 2026. PMID: 42803282. doi:10.1093/infdis/jiag488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。